128 related articles for article (PubMed ID: 36744309)
1. FDA grants accelerated approval for targeted therapy for platinum-resistant gynecologic cancers.
Nierengarten MB
Cancer; 2023 Mar; 129(5):656. PubMed ID: 36744309
[No Abstract] [Full Text] [Related]
2. New and Novel Therapies for Gynecologic Cancers.
Richardson DL
Semin Oncol Nurs; 2019 Apr; 35(2):217-219. PubMed ID: 30876683
[TBL] [Abstract][Full Text] [Related]
3. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
[TBL] [Abstract][Full Text] [Related]
5. U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
Arora S; Narayan P; Ison G; Berman T; Suzman DL; Wedam S; Prowell TM; Ghosh S; Philip R; Osgood CL; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
Clin Cancer Res; 2022 Mar; 28(6):1058-1071. PubMed ID: 34711631
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
7. New drugs in gynecologic cancer.
Daud A; Munster P; Munster P; Spriggs DR
Curr Treat Options Oncol; 2001 Apr; 2(2):119-28. PubMed ID: 12057130
[TBL] [Abstract][Full Text] [Related]
8. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
9. FDA accelerated approval benefits glioblastoma.
Cloughesy T
Lancet Oncol; 2010 Dec; 11(12):1120. PubMed ID: 21126686
[No Abstract] [Full Text] [Related]
10. FDA cancels approval for bevacizumab in advanced breast cancer.
Tanne JH
BMJ; 2011 Nov; 343():d7684. PubMed ID: 22121166
[No Abstract] [Full Text] [Related]
11. FDA and Avastin: crossroads in an era of targeted therapies.
Tripathy D
Oncology (Williston Park); 2010 Oct; 24(11):989-90. PubMed ID: 21155445
[No Abstract] [Full Text] [Related]
12. FDA grants approval to the RSV vaccine (nirsevimab-alip) for all infants: a leap forward for shielding the smallest.
Nazir A; Fatima R; Nazir A
Int J Surg; 2023 Dec; 109(12):3745-3746. PubMed ID: 38258995
[No Abstract] [Full Text] [Related]
13. FDA advisory panel recommends approval of drug for preoperative treatment of breast cancer.
Jin J
JAMA; 2013 Oct; 310(14):1434. PubMed ID: 24104359
[No Abstract] [Full Text] [Related]
14. Accelerated Approval of Aducanumab: Where Do We Stand Now?
Barenholtz Levy H
Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
[TBL] [Abstract][Full Text] [Related]
15. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
16. US FDA defends approval of Alzheimer's disease drug.
Jaffe S
Lancet; 2021 Jul; 398(10294):12. PubMed ID: 34217382
[No Abstract] [Full Text] [Related]
17. FDA pulls approval for avastin in breast cancer.
Rose S
Cancer Discov; 2011 Dec; 1(7):OF1-2. PubMed ID: 22586694
[TBL] [Abstract][Full Text] [Related]
18. Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2021 Sep; 27():e934854. PubMed ID: 34565792
[TBL] [Abstract][Full Text] [Related]
19. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
20. Lecanemab Gains FDA Approval for Early Alzheimer Disease.
Larkin HD
JAMA; 2023 Feb; 329(5):363. PubMed ID: 36652625
[No Abstract] [Full Text] [Related]
[Next] [New Search]
